Print Friendly, PDF & Email

We are reprogramming immune cells to target the most challenging autoimmune diseases and cancer

Leadership

Gregory Frost, Ph.D.

Chairman & Chief Executive Officer

Wendy Li, M.D.

Chief Medical Officer

Gregory Wade, Ph.D.

Chief Business Officer & Head of Finance

Lisa Feng, M.B.A.

Head of Asia & President, EXUMA Hong Kong

Richard Yan, C.P.A.

Vice President of Finance & Controller

​Gregory Schreiber, Ph.D.

Vice President, Intellectual Property & Licensing

Joshua Shi, Ph.D.

General Manager, Shenzhen EXUMA Biotech

EXUMA Biotech Company
© Copyright 2024 EXUMA Biotechnology. All rights reserved.

Website by Axxiem

Leadership

Gregory Frost, Ph.D.

Chairman & Chief Executive Officer

Gregory Frost, Ph.D. has served as Chairman and CEO of EXUMA Biotech since 2015. Dr. Frost has over 25 years of experience in the biotechnology industry, over a decade of which leading public biotechnology companies, where he helped create over $6B worth of shareholder value during his tenure. Dr. Frost was CEO at Halozyme Therapeutics (NASDAQ:HALO), an S&P 400 San Diego public biotechnology company he co-founded in 1999 to enable subcutaneous biologics delivery. He served in various operational roles over 15 years through multiple internal and partnered product approvals that are marketed in over 100 countries today.

Dr. Frost earned his B.A. in biochemistry and molecular biology from UCSC, his Ph.D. in the Department of Pathology at UCSF and performed postdoctoral research at the Sidney Kimmel Cancer Center. He sits on the Board of Governors at BioCom and is managing director of F1BioVentures, LLC.

Scientific Advisor

Wendy Li, M.D.

Chief Medical Officer

Dr. Wendy Li rejoined EXUMA Biotech as Chief Medical Officer in June 2024. She brings over 20 years of experience in global clinical and medical strategy management, spanning early to late-stage development of MNC pharmaceutical companies in the U.S. and Asia. Dr. Li’s expertise spans clinical development and medical affairs, where she has led numerous global clinical trials targeting hematological malignancies, solid tumors, and autoimmune disorders. She has successfully overseen and led multiple global therapeutic Investigational New Drug (IND) applications, New Drug Applications (NDA), and Biologics License Applications (BLA).

Before rejoining EXUMA, Dr. Li served as CMO for Gracell Biotechnologies, providing deliberate medical and clinical leadership for the cell therapy pipeline and strategies in the U.S. and Asia. She has also held leadership roles in clinical development and medical affairs at Pfizer, Sanofi, Genentech, and Sihuan Pharmaceutical. Dr. Li earned her M.D. from Sun Yat-Sen University of Medical Sciences.

Gregory Wade, Ph.D.

Chief Business Officer & Head of Finance

Dr. Wade serves as EXUMA Biotech’s Chief Business Officer and Head of Finance, having joined the company in 2022. Dr. Wade brings over 20 years of experience in the biotechnology industry. Most recently, he held the position of Managing Director, Capital Markets Advisory, and Co-Lead of the West Coast Region for Danforth Advisors. From 2015-2021, Dr. Wade was a Managing Director in BTIG’s Healthcare Investment Banking Group. Prior to his role with BTIG, Dr. Wade served as Head of Business Development at Pharmacyclics, a role he held following 16 years of work in healthcare equity research at Pacific Growth Equities and its successor, Wedbush PacGrow.

Dr. Wade earned his undergraduate degree in biophysics, and his Ph.D. in physiology, both from Western University in London, Canada.

Lisa Feng, M.B.A.

Head of Asia & President, EXUMA Hong Kong

Ms. Feng joined EXUMA Biotech in June 2024 and serves as Head of Asia and President of EXUMA Biotechnology Hong Kong. Prior to joining EXUMA, she was Chief Financial Officer and Chief Business Officer at Zhaoke Ophthalmology, a Hong Kong publicly traded company. At Zhaoke, she oversaw business strategy in addition to being responsible for the finance, investor relations, HR, IT/digital and legal functions.

Ms. Feng began her career in the US at McKinsey, followed by a decade in investment banking, including eight years at Goldman Sachs and two years at Standard Chartered Bank as its head of China Equity Capital Markets. Her banking experience includes M&A, IPO and debt/equity financing transactions. Prior to Zhaoke, she served as Chief Financial Officer of ACEA Therapeutics, a small molecule oncology company.

Ms. Feng received her bachelor’s and master’s degrees in computer science from Fudan University (China) and University of Virginia (US) respectively, and her MBA degree from University of Chicago Booth School of Business (US).

Richard Yan, C.P.A.

Vice President of Finance & Controller

Mr. Yan is a certified public accountant with over 25 years of experience in finance & accounting. He joined EXUMA Biotech in 2017 and currently serves as its Vice President of Finance & Controller, a role in which he oversees the finance, accounting, budgeting, tax, and treasury functions at all Company locations. Prior to joining EXUMA, he served in a similar role managing worldwide accounting, tax, and treasury functions at Premis Capital Partners. He began his career at Ernst & Young where he managed audit engagements.

Mr. Yan earned his B.B.A in accounting from Florida Atlantic University and has been a licensed certified public accountant since 1999.

​Gregory Schreiber, Ph.D.

Vice President, Intellectual Property & Licensing

Dr. Schreiber joined EXUMA Biotech in April 2016 and currently serves as its Vice President of Intellectual Property & Licensing. In his previous leadership roles over the past two decades at Intrexon Corporation, Thermo Fisher Scientific, and Johns Hopkins University, he led the licensing efforts that formed the basis of more than a dozen commercial products.

Dr. Schreiber received his B.A. in biochemistry from the University of California, Berkeley and his Ph.D. in immunology from Washington University in St. Louis. Additionally, he is registered to practice before the U.S. Patent and Trademark Office.

 

Joshua Shi, Ph.D.

General Manager, Shenzhen EXUMA Biotech

Dr. Shi is the General Manager of Shenzhen EXUMA Biotech, overseeing supply chain, manufacturing, quality control, and site operations at the Company’s lentivector manufacturing facility. Prior to EXUMA, he served as Vice President, CMC and Site Head of EdiGene where he led the development of the first gene editing HSC therapy in China. Prior to that, he held R&D and QA roles at Xiangxue Pharmaceutical in which he was responsible for the development of analytical methods for TCR-T product manufacturing; his work led to the first IND approval for a TCR-T product candidate in China.

Dr. Shi received his Ph.D. in physiology from China Agriculture University and holds the Senior Specialized Technique Qualification from the Beijing Municipal Medical Products Administration.

Gregory Frost, Ph.D.

Chairman & Chief Executive Officer

Gregory Frost, Ph.D. has served as Chairman and CEO of EXUMA Biotech since 2015. Dr. Frost has over 25 years of experience in the biotechnology industry, over a decade of which leading public biotechnology companies, where he helped create over $6B worth of shareholder value during his tenure. Dr. Frost was CEO at Halozyme Therapeutics (NASDAQ:HALO), an S&P 400 San Diego public biotechnology company he co-founded in 1999 to enable subcutaneous biologics delivery. He served in various operational roles over 15 years through multiple internal and partnered product approvals that are marketed in over 100 countries today.

Dr. Frost earned his B.A. in biochemistry and molecular biology from UCSC, his Ph.D. in the Department of Pathology at UCSF and performed postdoctoral research at the Sidney Kimmel Cancer Center. He sits on the Board of Governors at BioCom and is managing director of F1BioVentures, LLC.

Frank McCormick, Ph.D., F.R.S.

Dr. McCormick joined EXUMA Biotech as a Director in February 2020 and currently holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF where he serves as a Professor at the Helen Diller Family Comprehensive Cancer Center, after having previously served as the center’s director. Prior to joining UCSF, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held leadership positions with Cetus Corporation and Chiron Corporation. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated drug discovery efforts that led to the approval of Sorafenib for the treatment of renal cell and liver cancer, and the approval of ONYX-015 in China for the treatment of nasopharyngeal cancer. In addition, his group’s work led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Having authored over 330 scientific publications and holding over 20 issued patents, Dr. McCormick’s current research focuses on ways of targeting Ras proteins and their regulators, whereby he leads the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research to develop therapies against Ras-driven cancer.

Dr. McCormick earned his B.Sc. In biochemistry from the University of Birmingham, England and his Ph.D. in biochemistry from the University of Cambridge, England. He is a Fellow of the Royal Society and a member of the National Academy of Sciences, and served as president for the American Association for Cancer Research from 2012-2013.

David Ramsay, M.B.A.

Mr. Ramsay has been a Director of EXUMA Biotech since January 2017. In 2018, Mr. Ramsay served as Senior Vice President and Chief Financial Officer of Bonti, Inc. Mr. Ramsay retired from Halozyme Therapeutics, Inc. (NASDAQ: HALO) in July 2015, where he served as Chief Financial Officer since May 2013 and from 2003-2009. He also served as Halozyme’s Vice President, Corporate Development from 2009-2013. From 2000-2003, Mr. Ramsay was Vice President and Chief Financial Officer of Lathian Systems, Inc., a provider of technology-based sales solutions for the life science industry. From 1998-2000, he was with Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.), where he served as Vice President, Treasurer and Director, Corporate Finance. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his C.P.A. license. Mr. Ramsay also serves on the boards of Savara Pharmaceuticals (NASDAQ: SVRA) and La Jolla Pharmaceutical (NASDAQ: LJPC).

Mr. Ramsay holds a B.S. in business administration from the University of California, Berkeley and a M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.

Scott Segal, M.B.A.

Mr. Segal has been a Director of EXUMA Biotech since January 2020. Mr. Segal is a Managing Director at BDT & MSD Partners where he invests across a range of sectors, in both debt and structured equity. He joined MSD Partners (prior to its merger with BDT) in 2006 from the Boston Consulting Group where he provided consulting services to Fortune 500 executives. Prior to the Boston Consulting Group, Mr. Segal worked at HarbourVest Partners and Salomon Brothers.

Mr. Segal received his B.A. with honors from Queen’s University in Kingston, Canada, and his M.B.A. with honors from The Wharton School, University of Pennsylvania. Mr. Segal sits on the board of the Hudson Guild in New York City where he serves on the Executive Committee as the Treasurer.

 

Houston Holmes, M.D., M.B.A., F.A.C.P

Dr. Holmes joined EXUMA Biotech as a Director in December 2021. He is a hematologist/oncologist at Texas Oncology, where he serves on the Board of Directors and Executive Committee, and he is Area Medical Director of the Baylor/Sammons Cancer Center in Dallas. His clinical focus is in research and development of cell therapies for cancer.

Dr. Holmes received a B.S. in medical microbiology from Stanford University, an M.D. from the University of Texas Southwestern Medical School, and an M.B.A. from the University of Texas at Dallas. He completed an internship and residency in internal medicine at Baylor University Medical Center, and fellowship in medical oncology/hematology at the National Cancer Institute/National Heart, Lung, and Blood Institute. Dr. Holmes is a Fellow of the American College of Physicians.

Daniel L. Flynn, Ph.D.

Dr. Flynn was the founder of Deciphera Pharmaceuticals and served as Executive Vice President and Chief Scientific Officer of the company since January 2019, as well as Chief Scientific Officer since March 2014. He previously held the positions of President and Chief Executive Officer from November 2003 to March 2014 and was a member of the company’s Board of Directors from November 2003 to September 2015. Before founding the company in 2003, Dr. Flynn held senior roles in small molecule chemistry at various biotechnology and pharmaceutical companies, including Senior Director of Chemistry at Millennium Pharmaceuticals, Director of Medicinal Chemistry at Amgen Inc., and Director of Medicinal Chemistry, Combinatorial Chemistry, and Research Fellow at Monsanto Company, G.D. Searle Unit.

Dr. Flynn is currently an Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and has served as the national Chair for the Division of Medicinal Chemistry of the American Chemical Society. He received both his Ph.D. in medicinal chemistry and his B.S. in pharmacy from the University of Kansas and completed post-doctoral training in synthetic organic chemistry at Indiana University.

Share this page

Facebook
Twitter
LinkedIn
Email

Wendy Zhang, Ph.D.

Vice President, Alliance Management & Operations

Dr. Zhang has been leading EXUMA’s Asia team since 2016 and currently serves as Vice President of Alliance Management and Operations. Prior to EXUMA, she was Head of Biologics at BioDuro and held roles at Wuxi Apptec and aTyr Pharma Inc.. She served as the key scientist leading the in vitro assay development efforts while exploring the MOAs for the novel therapeutic Physiocrines. She was also responsible for establishing SOPs of release assays using human primary cells and tissues for leading candidates and evaluating CROs in Asia.

Dr. Zhang came to San Diego for her postdoctoral training at the Scripps Research Institute following her Ph.D. in molecular microbiology from the Chinese Academy of Sciences.

Board of Directors

Steven Frank, M.B.A.

Mr. Frank has been a Director of EXUMA since June 2020. He currently serves as Global Chairman Investment Banking – Healthcare at JP Morgan. Mr. Frank joined JP Morgan in 2008 during the merger between JP Morgan and Bear Stearns. He had been Head of the Bear Stearns Healthcare Investment Banking business from 1993-2008 and has provided general investment banking services to all types of healthcare companies. Prior to joining Bear Stearns, Mr. Frank served over ten years as an institutional investor, primarily at State Farm Insurance Company, where he focused on a multi-billion dollar life-sciences portfolio.

Mr. Frank holds a B.S. from Illinois State University and an M.B.A. from the University of Chicago.

.popup-arrows {display:none!important} #breadcrumbs {display:none!important} .skip-link{display:none!important} .elementor-shape-fill{display:none!important} .elementor-shape.elementor-shape-bottom { display: none; } span.elementor-icon-list-icon { display: none; } nav.elementor-nav-menu--dropdown{display:none!important} .eael-post-elements-readmore-btn{display:none!important} .eael-load-more-button{display:none!important}